Pricing Log in Create free account

Novogen Limited (KZIA) vs Rallybio Corporation (RLYB)

Novogen Limited and Rallybio Corporation are both Biotechnology companies. Novogen Limited and Rallybio Corporation are of similar size ($84.5M and $80.0M). Novogen Limited has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 3.3×. Across the 11 metrics below, Rallybio Corporation leads on 9 and Novogen Limited on 2.

Valuation

Metric KZIA RLYB Biotechnology median
P/E n/m 3.35 10.60
P/S — 104.91 9.40
P/B n/m 0.98 2.13
Price to free cash flow n/m 2.91 25.18
EV/EBITDA 1.46 0.03 0.66
EV/Sales n/m (0.79) 9.02
Earnings yield (2.99%) 29.85% (32.88%)
Free cash flow yield 0.00% 34.39% (23.13%)

Profitability

Metric KZIA RLYB Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 34.52% (51.96%)
Return on assets 0.00% 32.85% (46.06%)
Return on invested capital 0.00% (944.36%) 0.00%

Growth

Metric KZIA RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 6.76%
EPS growth (last fiscal year) 63.24% 85.06% 29.88%
Revenue growth, 5-year CAGR 11.56% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KZIA RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.87 28.87 4.97
Net debt to EBITDA 0.30 1.63 1.01

Dividend

Metric KZIA RLYB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KZIA RLYB Biotechnology median
Market cap 80.01m 84.47m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack